Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work.  The vision is of a common clinical-trial […] Continue reading ->
Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading ->
China’s COVID-19 situation is getting worse, and strategies to control the spread of the Omicron variant are getting stricter as the country registered 20,472 daily cases on Wednesday – the highest-ever infection rate. The epicentre of the outbreak is Shanghai, which recorded 17,007 cases on Wednesday and municipal authorities are conducting mass testing in the […] Continue reading ->
The COVID-19 pandemic has pushed the scientific community to start to implement a  ‘One Health’ approach – encompassing people, animals, plants and the environment – to ensure the early identification of infectious diseases and make the world a healthier place. The issues that “One Health” may tackle are diverse. They can range from curbing deforestation […] Continue reading ->
Moderna has committed to permanently waiving its COVID-19 patents in 92 low- and middle-income countries, and is pursuing vaccines for 15 diseases identified as the world’s biggest public health risk, including ebola, tuberculosis and malaria. The company has also offered outside researchers access to its mRNA technology to pursue research on emerging and neglected infectious […] Continue reading ->